Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totaling 240,809 shares, a drop of 65.7% from the September 15th total of 701,345 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average trading volume of 889,711 shares, the days-to-cover ratio is presently 0.3 days.
Azitra Price Performance
Shares of AZTR traded down $0.05 during midday trading on Tuesday, reaching $0.07. The stock had a trading volume of 2,670,554 shares, compared to its average volume of 746,577. Azitra has a 1-year low of $0.05 and a 1-year high of $1.09. The company’s fifty day simple moving average is $0.15 and its two-hundred day simple moving average is $0.18.
Azitra (NYSEAMERICAN:AZTR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). Equities analysts forecast that Azitra will post -0.20 EPS for the current fiscal year.
Azitra Company Profile
Azitra, Inc is a clinical-stage biotechnology company focused on developing live biotherapeutic products for dermatological conditions. The company uses microbiome science and genetic engineering to develop beneficial bacteria designed for topical application to the skin.
Azitra’s research programs have focused on conditions including atopic dermatitis, acne vulgaris and other skin disorders associated with impaired barrier function or microbial imbalance. Its pipeline has included engineered strains of skin-associated bacteria intended to deliver therapeutic proteins or other biological effects directly to affected areas.
The company was founded in 2014 and is based in New Haven, Connecticut.
Featured Stories
- Five stocks we like better than Azitra
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
